Moderna stock rises on early-stage hantavirus vaccine research with U.S. Army and Korean university.

Moderna's stock has rallied following news of its early-stage hantavirus vaccine research. The biotech company is conducting pre-clinical work with the U.S. Army and has partnered since 2024 with the Vaccine Innovation Center at Korea University College of Medicine to develop mRNA vaccines targeting hantaviruses. This research gains importance amid public concerns about a potential hantavirus outbreak from a cruise ship incident. While still in early stages, Moderna's work highlights its expanding focus beyond COVID-19 vaccines.